Case number 1:24-cv-01105
Galderma Laboratories, L.P. et al v. Macleods Pharmaceuticals Ltd. et al > Documents
| Date Field | Doc. No. | Description (Pages) |
|---|---|---|
| Nov 21, 2024 | 8 | SO ORDERED, re 7 Stipulation of Dismissal filed by TCD Royalty Sub LP, Galderma Laboratories, L.P. (CASE CLOSED) Signed by Judge Stephanos Bibas on 11/21/2024. (mpb) (Entered: 11/22/2024) (2) |
| Nov 21, 2024 | 9 | FINAL Report to the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 7,749,532 B2; 8,206,740 B2. (mpb) (Entered: 11/22/2024) (1) |
| Oct 22, 2024 | 7 | STIPULATION of Dismissal (without prejudice) - by Galderma Laboratories, L.P., TCD Royalty Sub LP. (Tigan, Jeremy) (Entered: 10/22/2024) (2) |
| Oct 9, 2024 | N/A | Case Assigned to Judge Stephanos Bibas of the United States Court of Appeals for the Third Circuit (due to related cases). Please include the initials of the Judge (SB) after the case number on all documents filed. (rjb) (Entered: 10/09/2024) (0) |
| Oct 4, 2024 | 1 | COMPLAINT filed for ANDA/PATENT INFRINGEMENT against Macleods Pharma USA, Inc., Macleods Pharmaceuticals Ltd. ( Filing fee $ 405, receipt number ADEDC-4515751.) - filed by Galderma Laboratories, L.P., TCD Royalty Sub LP. (Attachments: # 1 Exhibit A-B, # 2 Civil Cover Sheet)(scs) (Entered: 10/04/2024) (0) |
| Oct 4, 2024 | 2 | Notice, Consent and Referral forms re: U.S. Magistrate Judge jurisdiction. (scs) (Entered: 10/04/2024) (3) |
| Oct 4, 2024 | 3 | Supplemental information for patent cases involving an Abbreviated New Drug Application (ANDA) - Date Patentee(s) Received Notice: 08/22/2024. Date of Expiration of Patent: see attached.Thirty Month Stay Deadline: 2/22/2027. (scs) (Entered: 10/04/2024) (1) |
| Oct 4, 2024 | 4 | Disclosure Statement pursuant to Rule 7.1: identifying Corporate Parent Galderma Services Inc. for Galderma Laboratories, L.P.; Corporate Parent DRI Healthcare Trust, Corporate Parent DRI Healthcare Acquisitions LP for TCD Royalty Sub LP filed by Galderma Laboratories, L.P., TCD Royalty Sub LP. (scs) (Entered: 10/04/2024) (1) |
| Oct 4, 2024 | 5 | Summons Issued as to Macleods Pharma USA, Inc. on 10/4/2024; Macleods Pharmaceuticals Ltd. on 10/4/2024. (Attachments: # 1 Summons Issued)(scs) Modified on 10/4/2024 (scs). (Entered: 10/04/2024) (0) |
| Oct 4, 2024 | 6 | Report to the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 7,749,532 B2; 8,206,740 B2. (scs) (Entered: 10/04/2024) (1) |
